Ironwood Pharmaceuticals (IRWD) 15.15 $IRWD
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 4:36PM CST
TTS: 8.57 (-0.27), HK: 2.18 (-0.02), BTU: 7.65 (+0.46), IRWD: 15.15 (-0.85), CAG: 34.83 (-1.59), LOGM: 52.22 (+4.17), PES: 5.74 (+0.54), THRX: 14.85 (+1.00), HOS: 20.45 (+1.52), EGY: 5.86 (-0.06)
Ironwood Pharma updates guidance after Q4 results
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 9:38AM CST
IRWD: 15.15 (-0.85)
Weak On High Volume: Ironwood Pharmaceuticals (IRWD)
at The Street - Fri Feb 13, 9:02AM CST
Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a weak on high relative volume candidate
IRWD: 15.15 (-0.85)
Ironwood Pharmaceuticals Cuts Loss on Higher Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:22AM CST
Ironwood Pharmaceuticals (IRWD) reported a loss of 27 cents per share in the fourth quarter of 2014, wider than the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), ACT: 285.37 (+3.71), IRWD: 15.15 (-0.85), ACHN: 10.89 (-0.20)
Ironwood Pharmaceuticals' (IRWD) CEO Peter Hecht on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 9:28PM CST
IRWD: 15.15 (-0.85)
Ironwood reports 4Q loss
Automated Insights - Thu Feb 12, 4:42PM CST
CAMBRIDGE, Mass. (AP) _ Ironwood Pharmaceuticals Inc. (IRWD) on Thursday reported a loss of $37.6 million in its fourth quarter.
IRWD: 15.15 (-0.85)
Ironwood Pharmaceuticals (IRWD) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Feb 12, 3:25PM CST
IRWD: 15.15 (-0.85)
Ironwood Pharmaceuticals misses by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 3:08PM CST
IRWD: 15.15 (-0.85)
Ironwood Pharmaceuticals Provides Fourth Quarter 2014 Investor Update
Business Wire - Thu Feb 12, 3:02PM CST
--- LINZESS net sales of $93.8 million in fourth quarter; $297.0 million in 2014 -
IRWD: 15.15 (-0.85)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 4:35PM CST
TNGO: 12.11 (+0.42), ELLI: 50.06 (+2.67), WWWW: 16.59 (+0.64), CYBR: 52.52 (+6.83), JCOM: 65.83 (+6.29), DLR: 68.65 (-2.07), SFLY: 44.86 (-2.13), KRFT: 64.42 (-1.75), NR: 9.85 (+1.07), CGNX: 41.82 (+0.95), MTSN: 4.04 (+0.19), WAGE: 62.17 (+3.72), RGC: 23.23 (+1.35), VCRA: 9.86 (+0.68), ALNY: 95.54 (+1.67), AIZ: 61.44 (-4.98), AEL: 29.15 (+0.66), EGN: 69.90 (+3.59), INT: 53.72 (+2.28), LBTYA: 52.49 (+2.70), LOGM: 52.22 (+4.17), CUZ: 11.26 (+0.25), PRO: 23.01 (-0.85), ZNGA: 2.24 (-0.42), BCOR: 14.20 (-0.45), GRPN: 7.97 (+0.51), KING: 16.70 (+1.96), SSNC: 63.38 (+1.40), PFIE: 2.60 (-0.06), KN: 18.59 (-3.05), COLM: 51.50 (+7.91), RSG: 39.34 (-1.67), SSTK: 56.49 (-2.75), TCO: 74.67 (-5.21), INWK: 6.29 (+0.69), MGI: 8.61 (-0.83), DVA: 73.10 (-3.29), IRWD: 15.15 (-0.85), BYD: 14.36 (-0.23), QLIK: 31.17 (+1.09), MOBL: 9.53 (-0.21), RBCN: 4.53 (-0.13), AIG: 53.96 (+1.51), CBS: 59.83 (+2.06)
Ironwood Pharmaceuticals Approaching Profitability With LINZESS
Clinically Sound Investor - at Seeking Alpha - Fri Feb 06, 10:41AM CST
IRWD: 15.15 (-0.85)
Ironwood advances GERD candidate despite being marginally better than placebo
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 10:42AM CST
IRWD: 15.15 (-0.85)
Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastroesophageal Reflux Disease
Business Wire - Wed Feb 04, 7:01AM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that top-line data from an exploratory Phase IIa clinical study indicate IW-3718 improved heartburn and certain other symptoms associated with refractory gastroesophageal reflux disease (GERD). Based on these initial data, Ironwood intends to advance IW-3718 into a dose-ranging Phase IIb study.
IRWD: 15.15 (-0.85)
Synergy's Constipated Share Price Is Headed For A Cure
Scrying Biotech - at Seeking Alpha - Wed Feb 04, 5:30AM CST
SGYP: 2.98 (unch), IRWD: 15.15 (-0.85)
Ironwood Pharma reports February 12
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 3:52PM CST
IRWD: 15.15 (-0.85)
Ironwood Pharmaceuticals to Host Fourth Quarter 2014 Investor Update Call
Business Wire - Thu Jan 29, 3:00PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter 2014 investor update conference call and webcast at 4:30 p.m. Eastern Time on Thursday, February 12, 2015. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 73459881. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
IRWD: 15.15 (-0.85)
Why Earnings Season Could Be Great for Ironwood Pharmaceuticals (IRWD) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 16, 7:48AM CST
Investors are always looking for stocks that are poised to beat at earnings season and Ironwood Pharmaceuticals, Inc. (IRWD) may be one such company
IRWD: 15.15 (-0.85)
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 05, 3:22PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session that will begin at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.
IRWD: 15.15 (-0.85), JPM: 59.67 (+0.10)
Technical Report on Biotech Stocks -- MannKind, Amgen, Celldex Therapeutics, Juno Therapeutics, and Ironwood Pharma
PR Newswire - Wed Dec 31, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), Amgen Inc. (NASDAQ: AMGN), Celldex Therapeutics Inc. (NASDAQ: CLDX), Juno Therapeutics Inc. (NASDAQ: JUNO), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, December 30, 2014, the NASDAQ Composite ended at 4,777.44, down 0.61%, the Dow Jones Industrial Average lost 0.31%, to finish the day at 17,983.07, and the S&P 500 closed at 2,080.35, down 0.49%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 799.80, down 0.41%, while the index has advanced 8.09% in the previous three months. Register for your complimentary reports on these five stocks at:
IRWD: 15.15 (-0.85), CLDX: 20.97 (+0.53), AMGN: 153.48 (+0.30), JUNO: 40.52 (+0.18), MNKD: 7.00 (+0.02)
Ironwood Pharmaceuticals Advances IW-9179 to Phase IIa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 2:30PM CST
Ironwood Pharmaceuticals, Inc. (IRWD) started dosing patients in a phase IIa study on IW-9179 for the relief from symptoms associated with diabetic gastroparesis.
LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), IRWD: 15.15 (-0.85), SLXP: 152.35 (+3.17)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 4:36PM CST
TTS: 8.57 (-0.27), HK: 2.18 (-0.02), BTU: 7.65 (+0.46), IRWD: 15.15 (-0.85), CAG: 34.83 (-1.59), LOGM: 52.22 (+4.17), PES: 5.74 (+0.54), THRX: 14.85 (+1.00), HOS: 20.45 (+1.52), EGY: 5.86 (-0.06)
Ironwood Pharma updates guidance after Q4 results
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 9:38AM CST
IRWD: 15.15 (-0.85)
Weak On High Volume: Ironwood Pharmaceuticals (IRWD)
at The Street - Fri Feb 13, 9:02AM CST
Trade-Ideas LLC identified Ironwood Pharmaceuticals (IRWD) as a weak on high relative volume candidate
IRWD: 15.15 (-0.85)
Ironwood Pharmaceuticals Cuts Loss on Higher Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 13, 8:22AM CST
Ironwood Pharmaceuticals (IRWD) reported a loss of 27 cents per share in the fourth quarter of 2014, wider than the Zacks Consensus Estimate.
BIIB: 391.66 (-0.45), ACT: 285.37 (+3.71), IRWD: 15.15 (-0.85), ACHN: 10.89 (-0.20)
Ironwood Pharmaceuticals' (IRWD) CEO Peter Hecht on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 12, 9:28PM CST
IRWD: 15.15 (-0.85)
Ironwood reports 4Q loss
Automated Insights - Thu Feb 12, 4:42PM CST
CAMBRIDGE, Mass. (AP) _ Ironwood Pharmaceuticals Inc. (IRWD) on Thursday reported a loss of $37.6 million in its fourth quarter.
IRWD: 15.15 (-0.85)
Ironwood Pharmaceuticals (IRWD) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Feb 12, 3:25PM CST
IRWD: 15.15 (-0.85)
Ironwood Pharmaceuticals misses by $0.06, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 12, 3:08PM CST
IRWD: 15.15 (-0.85)
Ironwood Pharmaceuticals Provides Fourth Quarter 2014 Investor Update
Business Wire - Thu Feb 12, 3:02PM CST
--- LINZESS net sales of $93.8 million in fourth quarter; $297.0 million in 2014 -
IRWD: 15.15 (-0.85)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 4:35PM CST
TNGO: 12.11 (+0.42), ELLI: 50.06 (+2.67), WWWW: 16.59 (+0.64), CYBR: 52.52 (+6.83), JCOM: 65.83 (+6.29), DLR: 68.65 (-2.07), SFLY: 44.86 (-2.13), KRFT: 64.42 (-1.75), NR: 9.85 (+1.07), CGNX: 41.82 (+0.95), MTSN: 4.04 (+0.19), WAGE: 62.17 (+3.72), RGC: 23.23 (+1.35), VCRA: 9.86 (+0.68), ALNY: 95.54 (+1.67), AIZ: 61.44 (-4.98), AEL: 29.15 (+0.66), EGN: 69.90 (+3.59), INT: 53.72 (+2.28), LBTYA: 52.49 (+2.70), LOGM: 52.22 (+4.17), CUZ: 11.26 (+0.25), PRO: 23.01 (-0.85), ZNGA: 2.24 (-0.42), BCOR: 14.20 (-0.45), GRPN: 7.97 (+0.51), KING: 16.70 (+1.96), SSNC: 63.38 (+1.40), PFIE: 2.60 (-0.06), KN: 18.59 (-3.05), COLM: 51.50 (+7.91), RSG: 39.34 (-1.67), SSTK: 56.49 (-2.75), TCO: 74.67 (-5.21), INWK: 6.29 (+0.69), MGI: 8.61 (-0.83), DVA: 73.10 (-3.29), IRWD: 15.15 (-0.85), BYD: 14.36 (-0.23), QLIK: 31.17 (+1.09), MOBL: 9.53 (-0.21), RBCN: 4.53 (-0.13), AIG: 53.96 (+1.51), CBS: 59.83 (+2.06)
Ironwood Pharmaceuticals Approaching Profitability With LINZESS
Clinically Sound Investor - at Seeking Alpha - Fri Feb 06, 10:41AM CST
IRWD: 15.15 (-0.85)
Ironwood advances GERD candidate despite being marginally better than placebo
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 10:42AM CST
IRWD: 15.15 (-0.85)
Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastroesophageal Reflux Disease
Business Wire - Wed Feb 04, 7:01AM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that top-line data from an exploratory Phase IIa clinical study indicate IW-3718 improved heartburn and certain other symptoms associated with refractory gastroesophageal reflux disease (GERD). Based on these initial data, Ironwood intends to advance IW-3718 into a dose-ranging Phase IIb study.
IRWD: 15.15 (-0.85)
Synergy's Constipated Share Price Is Headed For A Cure
Scrying Biotech - at Seeking Alpha - Wed Feb 04, 5:30AM CST
SGYP: 2.98 (unch), IRWD: 15.15 (-0.85)
Ironwood Pharma reports February 12
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 3:52PM CST
IRWD: 15.15 (-0.85)
Ironwood Pharmaceuticals to Host Fourth Quarter 2014 Investor Update Call
Business Wire - Thu Jan 29, 3:00PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its fourth quarter 2014 investor update conference call and webcast at 4:30 p.m. Eastern Time on Thursday, February 12, 2015. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 73459881. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
IRWD: 15.15 (-0.85)
Why Earnings Season Could Be Great for Ironwood Pharmaceuticals (IRWD) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 16, 7:48AM CST
Investors are always looking for stocks that are poised to beat at earnings season and Ironwood Pharmaceuticals, Inc. (IRWD) may be one such company
IRWD: 15.15 (-0.85)
Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Business Wire - Mon Jan 05, 3:22PM CST
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2015 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time at the Westin St. Francis Hotel in San Francisco. The presentation will be followed by a question and answer session that will begin at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.
IRWD: 15.15 (-0.85), JPM: 59.67 (+0.10)
Technical Report on Biotech Stocks -- MannKind, Amgen, Celldex Therapeutics, Juno Therapeutics, and Ironwood Pharma
PR Newswire - Wed Dec 31, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), Amgen Inc. (NASDAQ: AMGN), Celldex Therapeutics Inc. (NASDAQ: CLDX), Juno Therapeutics Inc. (NASDAQ: JUNO), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, December 30, 2014, the NASDAQ Composite ended at 4,777.44, down 0.61%, the Dow Jones Industrial Average lost 0.31%, to finish the day at 17,983.07, and the S&P 500 closed at 2,080.35, down 0.49%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 799.80, down 0.41%, while the index has advanced 8.09% in the previous three months. Register for your complimentary reports on these five stocks at:
IRWD: 15.15 (-0.85), CLDX: 20.97 (+0.53), AMGN: 153.48 (+0.30), JUNO: 40.52 (+0.18), MNKD: 7.00 (+0.02)
Ironwood Pharmaceuticals Advances IW-9179 to Phase IIa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 2:30PM CST
Ironwood Pharmaceuticals, Inc. (IRWD) started dosing patients in a phase IIa study on IW-9179 for the relief from symptoms associated with diabetic gastroparesis.
LCI: 57.78 (-0.91), ACT: 285.37 (+3.71), IRWD: 15.15 (-0.85), SLXP: 152.35 (+3.17)
